Lees ook:

https://kanker-actueel.nl/studiepublicaties-van-niet-toxische-middelen-en-behandelingen-uit-literatuurlijst-van-arts-bioloog-drs-engelbert-valstar-gerelateerd-aan-borstkanker.html

en dit artikel:

https://kanker-actueel.nl/NL/palpociclib-plus-fulvestrand-geeft-langere-overall-overleving-en-progressievrije-ziekte-dan-alleen-fulvesrtrand-bij-hormoonresistente-borstkanker.html

19 april 2018: Bron: Journal of Clinical Oncology

Abemaciclib, een zogeheten kinaseremmer zoals ook palpociclib is, gegeven naast fulvestrant geeft een verbeterde progressievrije ziekte en een verbeterde overall overleving bij die patiënten waarbij abemaciclib aansloeg in vergelijking met alleen fulvestrant plus placebo.
PFS was mediaan, 16,4 v 9,3 maanden, hazard ratio, 0,553, 95% CI, 0,449 tot 0,681; P <.001).
Abemaciclib plus fulvestrant waarbij de aanpak aansloeg gaf een overall overleving (ORR) van 48,1% (95% CI, 42,6% tot 53,6%) in vergelijking met 21,3% (95% CI, 15,1% tot 27,6%) in de controlegroep.

Wel waren er voor abemaciclib behoorlijk wat meer bijwerkingen. De meest voorkomende bijwerkingen in de abemaciclib versus placebogroep waren diarree (86,4% versus 24,7%), neutropenie (46,0% v 4,0%), misselijkheid (45,1% versus 22,9%) en vermoeidheid (39,9% versus 26,9%).

Dit alles blijkt uit de resultaten van de fase III MONARCH-2 studie bij totaal 669 deelnemende patiënten. Abemaciclib plus fulvestrant (n = 446) of placebo plus fulvestrant (n = 223)

Uit het volledige studierapport: MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy dat gratis is in te zien hier de grafieken van de resultaten. Abstract plus referentielijst staat onderaan artikel.

Progressieziektevrije grafiek: Fig 2. Kaplan-Meier plots of progression-free survival. (A) Investigator-assessed and (B) independent central review of intent-to-treat population. HR, hazard ratio.

Overall overlevingsgrafiek hieronder:

Fig 4. Tumor response. (A) Best percent change in tumor size for all evaluable patients. Dotted horizontal line (−30%) corresponds to the partial response criteria defined by RECIST version 1.1. The vertical line is a visual to locate approximately 50% of patients. (B) Percentage change in tumor size from baseline by cycle (at day 1 of each cycle).

Conclusie van de onderzoekers:

Abemaciclib met 150 mg tweemaal daags plus fulvestrant was effectief, waardoor PFS en ORR significant werden verbeterd en een aanvaardbaar veiligheidsprofiel werd aangetoond bij vrouwen met hormoonreceptorpositieve en humane epidermale groeifactor receptor 2-negatieve gevorderde borstkanker die ziekte progressie vertoonden tijdens de hormoontherapie.

Het volledige studierapport: MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy is gratis in te zien.

Abstract plus referentielijst:

Abemaciclib plus fulvestrant was an effective treatment for patients with HR+/HER2− ABC whose disease progressed while they were receiving ET.

DOI: 10.1200/JCO.2017.73.7585 Journal of Clinical Oncology 35, no. 25 (September 1 2017) 2875-2884.

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

George W. Sledge, Jr., Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot...Show More

Purpose

MONARCH 2 (ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC).

Patients and Methods

MONARCH 2 was a global, double-blind, phase III study of women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who had progressed while receiving neoadjuvant or adjuvant endocrine therapy (ET), ≤ 12 months from the end of adjuvant ET, or while receiving first-line ET for metastatic disease. Patients were randomly assigned 2:1 to receive abemaciclib or placebo (150 mg twice daily) on a continuous schedule and fulvestrant (500 mg, per label). The primary end point was investigator-assessed progression-free survival (PFS), and key secondary end points included overall survival, objective response rate (ORR), duration of response, clinical benefit rate, quality of life, and safety.

Results

Between August 2014 and December 2015, 669 patients were randomly assigned to receive abemaciclib plus fulvestrant (n = 446) or placebo plus fulvestrant (n = 223). Abemaciclib plus fulvestrant significantly extended PFS versus fulvestrant alone (median, 16.4 v 9.3 months; hazard ratio, 0.553; 95% CI, 0.449 to 0.681; P < .001). In patients with measurable disease, abemaciclib plus fulvestrant achieved an ORR of 48.1% (95% CI, 42.6% to 53.6%) compared with 21.3% (95% CI, 15.1% to 27.6%) in the control arm. The most common adverse events in the abemaciclib versus placebo arms were diarrhea (86.4% v 24.7%), neutropenia (46.0% v 4.0%), nausea (45.1% v 22.9%), and fatigue (39.9% v 26.9%).

Conclusions

Abemaciclib at 150 mg twice daily plus fulvestrant was effective, significantly improving PFS and ORR and demonstrating a tolerable safety profile in women with hormone receptor-positive and human epidermal growth factor receptor 2-negative ABC who progressed while receiving ET.

REFERENCES

1.	Lobbezoo DJ, van Kampen RJ, Voogd AC, et al: Prognosis of metastatic breast cancer subtypes: The hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141:507-514, 2013 Crossref, Medline
2.	Rugo HS, Rumble RB, Macrae E, et al: Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol 34:3069-3103, 2016 Link
3.	Milani A, Geuna E, Mittica G, et al: Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. World J Clin Oncol 5:990-1001, 2014 Crossref, Medline
4.	Dickler MN, Tolaney SM, Rugo HS, et al: MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease. J Clin Oncol 34, 2016 (suppl; abstr 510)
5.	Cristofanilli M, Turner NC, Bondarenko I, et al: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425-439, 2016 Medline
6.	Hortobagyi GN, Stemmer SM, Burris HA, et al: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375:1738-1748, 2016 Crossref, Medline
7.	Lukas J, Bartkova J, Bartek J: Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol 16:6917-6925, 1996 Crossref, Medline
8.	Altucci L, Addeo R, Cicatiello L, et al: 17beta-Estradiol induces cyclin D1 gene transcription, p36D1-p34cdk4 complex activation and p105Rb phosphorylation during mitogenic stimulation of G(1)-arrested human breast cancer cells. Oncogene 12:2315-2324, 1996 Medline
9.	Bartkova J, Lukas J, Müller H, et al: Cyclin D1 protein expression and function in human breast cancer. Int J Cancer 57:353-361, 1994 Crossref, Medline
10.	Patnaik A, Rosen LS, Tolaney SM, et al: Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors. Cancer Discov 6:740-753, 2016 Crossref, Medline
11.	Matsushime H, Ewen ME, Strom DK, et al: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 71:323-334, 1992 Crossref, Medline
12.	Meyerson M, Harlow E: Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol 14:2077-2086, 1994 Crossref, Medline
13.	Anders L, Ke N, Hydbring P, et al: A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells. Cancer Cell 20:620-634, 2011 Crossref, Medline
14.	Zou X, Ray D, Aziyu A, et al: Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 16:2923-2934, 2002 Crossref, Medline
15.	Gelbert LM, Cai S, Lin X, et al: Preclinical characterization of the CDK4/6 inhibitor LY2835219: In-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine. Invest New Drugs 32:825-837, 2014 Crossref, Medline
16.	Lallena MJ, Boehnke K, Torres R, et al: In-vitro characterization of abemaciclib pharmacology in ER+ breast cancer cell lines. Cancer Res 75, 2015 (15 suppl; abstract nr 3101)
17.	Pfizer: Ibrance package insert. http://labeling.pfizer.com/ShowLabeling.aspx?id=2191
18.	Novartis Pharmaceuticals: Kisqali package insert. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209092s000lbl.pdf
19.	Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009 Crossref, Medline
20.	Cardoso F, Costa A, Norton L, et al: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489-502, 2014 Crossref, Medline
21.	Cardoso F, Costa A, Norton L, et al: ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871-1888, 2014 Crossref, Medline
22.	Di Leo A, Jerusalem G, Petruzelka L, et al: Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28:4594-4600, 2010 Link
23.	Tolaney SM, Lam AQ, Mukundan S, et al: Analysis of renal function in MONARCH 1: A phase 2 study of abemaciclib, a CDK4 & 6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for Metastatic Breast Cancer (MBC). Cancer Res 77, 2017 (4 suppl; abstract nr P6-15-01)
24.	Yardley DA, Noguchi S, Pritchard KI, et al: Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870-884, 2013 [Erratum: Adv Ther 31:1008-1009, 2014]
25.	American Association for Cancer Research: PI3K Inhibitor Improves PFS in BELLE-2 Trial. Cancer Discov 6:115-116, 2016
26.	Di Leo A, Seok Lee K, Ciruelos E, et al: BELLE-3: A phase III study of buparlisib + fulvestrant in postmenopausal women with HR+, HER2–, aromatase inhibitor-treated, locally advanced or metastatic breast cancer, who progressed on or after mTOR inhibitor-based treatment. Cancer Res 77, 2017 (4 suppl; abstract nr S4-07)
27.	Bergh J, Jönsson PE, Lidbrink EK, et al: FACT: An open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 30:1919-1925, 2012 Link
28.	Flaherty KT, Lorusso PM, Demichele A, et al: Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res 18:568-576, 2012 Crossref, Medline
29.	Juric D, Campone M, Ismail-Khan R, et al: Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2– breast cancer: Safety, preliminary efficacy and molecular analysis. Cancer Res 75, 2015 (9 suppl; abstract nr P5-19-24)
30.	Hurvitz S, Abad MF, Rostorfer R, et al: Interim results from neoMONARCH: A neoadjuvant phase II study of abemaciclib in postmenopausal women with HR+/HER2- breast cancer. Ann Oncol 27, 2016 (suppl_6; abstract LBA13)